#GynCSM
LightNews LightNews
onclive.bsky.social
📈 The IDMC overseeing an ongoing phase 2 MRD translational study of IMNN-001 in newly diagnosed advanced ovarian cancer has recommended the trial continue without modification. #gyncsm #oncology

More insights ➡️: www.onclive.com/view/idmc-re...
IDMC Recommends Continuation of Phase 2 MRD Study of IMNN-001 in Advanced Ovarian Cancer | OncLive
An IDMC recommended continuing a phase 2 minimal residual disease study of IMNN-001 without modification following a favorable safety review.
www.onclive.com
September 23, 2026 at 4:29 PM
onclive.bsky.social
Responses to ADC TUB-040 did not differ by NaPi2b expression level in platinum-resistant ovarian cancer, supporting a biomarker-unrestricted development path, according to Toon Van Gorp, MD, PhD. @ascocancer.bsky.social #ASCO26 #gyncsm #oncology

More insights ➡️: www.onclive.com/view/napista...
NAPISTAR-1-01 Data Support Rapid TUB-040 Development in Biomarker-Unrestricted Ovarian Cancer | OncLive
Toon Van Gorp, MD, PhD, discusses key data with TUB-040 in platinum-resistant ovarian cancer and next steps for development.
www.onclive.com
September 21, 2026 at 6:23 PM
onclive.bsky.social
WATCH: Lucy Gilbert, MD, MSc, FRCOG, discusses data from the ROSELLA trial of relacorilant plus nab-paclitaxel in platinum-resistant ovarian cancer. @ascocancer.bsky.social #ASCO26 #gyncsm #oncology

Full video ➡️: www.onclive.com/view/dr-gilb...
Dr Gilbert on the Efficacy of Relacorilant Plus Nab-Paclitaxel in Ovarian Cancer | OncLive
Lucy Gilbert, MD, MSc, FRCOG, discusses data from the ROSELLA trial of relacorilant plus nab-paclitaxel in platinum-resistant ovarian cancer.
www.onclive.com
September 18, 2026 at 8:39 PM
onclive.bsky.social
📰 @ascocancer.bsky.social published its first living guideline on the treatment of recurrent high-grade serous and/or endometrioid epithelial ovarian, fallopian tube, or primary peritoneal cancer. @jco-asco.bsky.social #gyncsm #oncology

Learn more: www.onclive.com/view/asco-is...
ASCO Issues First Living Guideline for Systemic Treatment of Recurrent Ovarian Cancer | OncLive
ASCO's first living guideline backs platinum doublets and mirvetuximab soravtansine for FRα+, high-grade platinum-resistant ovarian cancer.
www.onclive.com
September 15, 2026 at 2:11 PM
onclive.bsky.social
Sapanisertib and serabelisib plus paclitaxel received @fda.gov fast track designation for pretreated advanced PI3K/AKT/mTOR pathway–altered endometrial cancer. #gyncsm #oncology

www.onclive.com/view/fda-gra...
FDA Grants Fast Track Designation to Sapanisertib and Serabelisib Plus Paclitaxel in Advanced Endometrial Cancer | OncLive
Sapanisertib and serabelisib plus paclitaxel received FDA fast track designation for pretreated advanced PI3K/AKT/mTOR pathway–altered endometrial cancer.
www.onclive.com
August 17, 2026 at 4:34 PM
onclive.bsky.social
Antibodies directed against TNFR2, a regulator in the TME that promotes tumor cell proliferation, have shown promise in T-cell lymphoma and ovarian cancer. #gyncsm #lymsm #oncology

www.onclive.com/view/tnfr2-a...
TNFR2 Advances as a Novel Target for Restoring Antitumor Immunity Across Lymphoma and Solid Tumors | OncLive
Antibodies directed against TNFR2, a regulator in the TME that promotes tumor cell proliferation, have shown promise in T-cell lymphoma and ovarian cancer.
www.onclive.com
August 11, 2026 at 1:16 PM
onclive.bsky.social
PD-L1 IHC 22C3 pharmDx gained EU approval as a companion diagnostic for pembrolizumab in platinum-resistant epithelial ovarian cancer. #gyncsm #oncology

www.onclive.com/view/eu-clea...
EU Clears PD-L1 IHC 22C3 pharmDx as Companion Diagnostic for Pembrolizumab in Ovarian Cancer | OncLive
PD-L1 IHC 22C3 pharmDx gained EU approval as a companion diagnostic for pembrolizumab in platinum-resistant epithelial ovarian cancer.
www.onclive.com
August 6, 2026 at 1:55 PM
dsmgyo.bsky.social
#Lenvatinib plus #pembrolizumab after (neo)adjuvant #carboplatin & #paclitaxel.

#gyncsm #clinicaltrial #endometrialcancer
August 3, 2026 at 10:35 PM
onclive.bsky.social
Premal H. Thaker, MD, MS, discusses INCB123667 in ovarian cancer and the ongoing MAESTRA 2 study. @washumedicine.bsky.social #gyncsm #oncology

www.onclive.com/view/incb123...
INCB123667 Advances to Phase 3 Following Encouraging Activity in Platinum-Resistant Ovarian Cancer | OncLive
Premal H. Thaker, MD, MS, discusses INCB123667 in ovarian cancer and the ongoing MAESTRA 2 study.
www.onclive.com
July 8, 2026 at 7:13 PM
emilydrake.ca
All are welcome to the #AYACSM (Adolescent and Young Adult Cancer Societal Movement) #SkyChat starting now!

#BTSM #BCSM #LCSM #AYACancer #OncSky #GYNCSM
Fran Drescher's Enthusiastic Welcome
ALT: Fran Drescher's Enthusiastic Welcome
static.klipy.com
July 8, 2026 at 12:03 AM
jco-asco.bsky.social
New content alert: Diagnostic Accuracy and Concordance of Self-Collected Cervical CDO1 and CELF4 Methylation Testing Compared With Physician Sampling for Endometrial Cancer Detection.

Read the article: https://bit.ly/4euYJxv
#gyncsm
June 26, 2026 at 4:00 PM
onclive.bsky.social
🎗️ @myesmo.bsky.social #ESMOGynae2026: Trastuzumab pamirtecan demonstrated durable activity and promising survival in previously treated HER2-expressing #EndometrialCancer. #gyncsm @unmc.bsky.social

📈 ORR: 44.1%
⏳ Median PFS: 8.0 months
⬆️ Median OS: 15.0 months

www.onclive.com/view/trastuz...
Trastuzumab Pamirtecan Provides Meaningful Survival Benefit in Pretreated HER2-Expressing Endometrial Cancer | OncLive
Trastuzumab pamirtecan produced durable responses and encouraging survival in HER2-expressing endometrial cancer after prior therapy.
www.onclive.com
June 17, 2026 at 9:29 PM
tumorijournal.bsky.social
#gyncsm #CanSky What emerges from the most recent first-line trials is that progress in advanced #ovariancancer depends not only on new treatment, but on better patient selection.
Appropriate treatment must be determined for each individual: best treatment for each patient

omny.fm/shows/tumori...
June 12, 2026 at 10:02 AM
lmg622.bsky.social
In a review published in the Journal of Cancer Research & Clinical Oncology, researchers sought to answer two questions: “Is #HRT appropriate in #BRCA carriers with a history of TNBC following BSO, & if so, under what clinical conditions?

#bcsm #gyncsm #openaccess #hereditarycancer #womenshealth
Hormonal management after risk-reducing surgery in BRCA-mutated triple-negative breast cancer survivors - Journal of Cancer Research and Clinical Oncology
Premenopausal women carrying a BRCA1 or BRCA2 mutation are frequently advised to undergo risk-reducing bilateral salpingo-oophorectomy (BSO) to lower their significantly increased lifetime risk of ova...
link.springer.com
June 1, 2026 at 5:33 PM
ascocancer.bsky.social
New research from #ASCO26 shows that fasting before and after chemo may help reduce insulin levels and may help improve tx response for certain people with #ovariancancer. @drteplinsky.bsky.social explains more in our latest Science in Seconds: https://bit.ly/4f7z1Qm
#gyncsm
May 30, 2026 at 2:18 PM
onclive.bsky.social
Thanks to Dr Lucy Gilbert of @mcgilluniversity.bsky.social for joining us at #ASCO26 to highlight an analysis of the ROSELLA trial of relacorilant plus nab-paclitaxel in PROC! @ascocancer.bsky.social #gyncsm #oncology

See our site for exclusive meeting updates!

www.onclive.com/conference/a...
May 29, 2026 at 6:56 PM
tumorijournal.bsky.social
#gyncsm #CanSky What emerges from the most recent first-line trials is that progress in advanced #ovariancancer depends not only on new treatment, but on better patient selection.
Appropriate treatment must be determined for each individual: best treatment for each patient

omny.fm/shows/tumori...
May 28, 2026 at 2:02 PM
onclive.bsky.social
#ASCO26 abstract release: Data from the RUBY trial with dostarlimab-gxly plus chemo in patients w/ dMMR/MSI-H primary advanced/recurrent endometrial cancer.

@uwmedicine.bsky.social @sitemancenter.bsky.social @ascocancer.bsky.social #gyncsm #oncology

www.onclive.com/view/dostarl...
Dostarlimab Combo Shows Durable Disease Control in dMMR/MSI-H Endometrial Cancer, Full Data Due at ASCO 2026 | OncLive
Data from the ENGOT-ENG-NSGO/GOG-3031/RUBY trial have been released via abstract ahead of the 2026 ASCO Annual Meeting.
www.onclive.com
May 21, 2026 at 11:43 PM
onclive.bsky.social
🚨BREAKING🚨

The 2026 #GiantsofCancerCare class has been announced‼️

🏆 Check out our site to learn more about the 14th annual class of inductees ➡️: www.onclive.com/view/giants-...

#oncology #mmsm #bcsm #lcsm #pcsm #lymsm #hncsm #leusm #gyncsm
Giants of Cancer Care Announces the 14th Annual Class of Inductees | OncLive
OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.
www.onclive.com
May 15, 2026 at 3:21 PM
tumorijournal.bsky.social
#GYN #Cancer | Expectant management or conization for persistent low-grade cervical intraepithelial neoplasia: Analysis of 5-year outcomes

🔓https://journals.sagepub.com/share/S76SVMZPIET4GBD7AGCH?target=10.1177/03008916251395597

#HPV #GYNCSM
April 30, 2026 at 5:01 PM
tumorijournal.bsky.social
#GynOnc #GYNCsm | Abdominal specimen retrieval in #endometrial cancer patients with large #uteri
⬇️
Learn more at the🔓link
journals.sagepub.com/share/EDBHID...
April 21, 2026 at 2:01 PM
onclive.bsky.social
🧬 Mirvetuximab soravtansine + carboplatin demonstrated encouraging antitumor activity in platinum-sensitive ovarian cancer, supporting expansion of this ADC beyond the platinum-resistant setting. 📊
Read more ➡️ www.onclive.com/view/mirvetu... #gyncsm #oncology #SGOAM26
Mirvetuximab Soravtansine Plus Carboplatin Is Active in Platinum-Sensitive Ovarian Cancer | OncLive
Mirvetuximab soravtansine plus carboplatin showed antitumor activity and a manageable safety profile in patients with recurrent platinum-sensitive ovarian cancer.
www.onclive.com
April 13, 2026 at 9:27 PM
onclive.bsky.social
💊 Promising data from #SGOAM26: Tisotumab vedotin + carboplatin + pembrolizumab ± bevacizumab delivered a 65.8% response rate and a median OS of 28 months in first-line recurrent/metastatic cervical cancer.

Learn more: 🔗 www.onclive.com/view/tisotum... #gyncsm #medtwitter #oncology
Tisotumab Vedotin With Carboplatin/Pembrolizumab ± Bevacizumab Shows Activity in Cervical Cancer | OncLive
Tisotumab vedotin plus carboplatin & pembrolizumab ± bevacizumab achieved 65.8% ORR and 28-month median OS in first-line recurrent/metastatic cervical cancer.
www.onclive.com
April 13, 2026 at 9:18 PM
onclive.bsky.social
🧬 Sofetabart mipitecan (LY4170156) demonstrated ~50% ORR and 78% disease control, with responses observed regardless of FRα expression and prior ADC exposure in early-phase data. 📊
Read more ➡️ www.onclive.com/view/sofetab...
#SGOAM26 #gyncsm
Sofetabart Mipitecan Displays Antitumor Activity in Recurrent Platinum-Resistant HGSOC | OncLive
Sofetabart mipitecan elicited strong antitumor activity in recurrent platinum-resistant high-grade serous ovarian cancer.
www.onclive.com
April 13, 2026 at 2:40 PM
onclive.bsky.social
🔬 New data from #SGOAM26: The ADC trastuzumab pamirtecan hit a ~50% response rate in pretreated HER2-expressing endometrial cancer, with responses lasting nearly 10 months.

Learn more 🔗: www.onclive.com/view/trastuz...

#gyncsm #gynonc
Trastuzumab Pamirtecan Elicits Responses in HER2-Expressing Advanced/Metastatic Endometrial Cancer | OncLive
Trastuzumab pamirtecan achieved ~50% ORR in pretreated HER2-expressing endometrial cancer, earning FDA breakthrough designation per phase 1/2 trial data.
www.onclive.com
April 11, 2026 at 6:09 PM